Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Dissecting FAP+ Cell Diversity in Pancreatic Cancer Uncovers an Interferon-Response Subtype of Cancer-Associated Fibroblasts with Tumor-Restraining Properties

Cumming, Joshua ; Maneshi, Parniyan ; Dongre, Mitesh ; Alsaed, Tala ; Dehghan-Nayeri, Mohammad Javad ; Ling, Agnes ; Pietras, Kristian LU orcid ; Patthey, Cedric and Öhlund, Daniel (2025) In Cancer Research 85(13). p.2388-2411
Abstract

Within the stroma of pancreatic ductal adenocarcinoma (PDAC), mesenchymal cells differentiate into cancer-associated fibroblast (CAF) subtypes that differentially mediate disease progression. Defining the regulatory mechanism and diversity of CAF subtypes could identify potential therapeutic strategies to harness the tumor-suppressive activities of CAFs. To address this, we utilized single-cell RNA sequencing to profile fibroblast activation protein-α (FAP)–expressing mesenchymal cells in human PDAC. The mesenchymal subpopulations in PDAC reflected mesenchymal cell heterogeneity found in the normal developing pancreas. In addition to characterizing inflammatory CAF and myofibroblastic CAF subpopulations in detail, the analysis uncovered... (More)

Within the stroma of pancreatic ductal adenocarcinoma (PDAC), mesenchymal cells differentiate into cancer-associated fibroblast (CAF) subtypes that differentially mediate disease progression. Defining the regulatory mechanism and diversity of CAF subtypes could identify potential therapeutic strategies to harness the tumor-suppressive activities of CAFs. To address this, we utilized single-cell RNA sequencing to profile fibroblast activation protein-α (FAP)–expressing mesenchymal cells in human PDAC. The mesenchymal subpopulations in PDAC reflected mesenchymal cell heterogeneity found in the normal developing pancreas. In addition to characterizing inflammatory CAF and myofibroblastic CAF subpopulations in detail, the analysis uncovered a previously undescribed interferon-response CAF (ifCAF) subtype. Tumor-derived signals induced specific CAF subtypes from pancreatic stellate cells in an organoid-based coculture model, and time-course experiments revealed regulatory mechanisms that govern subtype formation. STING agonists promoted an ifCAF phenotype in vivo and in vitro. Importantly, induction of an ifCAF phenotype suppressed tumor cell invasiveness and induced an antitumor phenotype in tumor-associated neutrophils. Together, this study resolves FAP+ stromal cell heterogeneity in PDAC and identifies an ifCAF subtype that can be induced to suppress protumorigenic features of PDAC. Significance: Characterization of FAP+ mesenchymal cell heterogeneity in pancreatic cancer identifies a tumor-suppressive interferon-response cancer-associated fibroblast subtype that can be induced by stimulating type I interferon signaling using STING agonists.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer Research
volume
85
issue
13
pages
24 pages
publisher
American Association for Cancer Research Inc.
external identifiers
  • scopus:105009938685
  • pmid:40215177
ISSN
0008-5472
DOI
10.1158/0008-5472.CAN-23-3252
language
English
LU publication?
yes
additional info
Publisher Copyright: ©2025 The Authors; Published by the American Association for Cancer Research.
id
b700e6e7-f940-4f8c-98ab-e9e20ecd46fb
date added to LUP
2025-12-11 10:05:53
date last changed
2025-12-12 03:11:17
@article{b700e6e7-f940-4f8c-98ab-e9e20ecd46fb,
  abstract     = {{<p>Within the stroma of pancreatic ductal adenocarcinoma (PDAC), mesenchymal cells differentiate into cancer-associated fibroblast (CAF) subtypes that differentially mediate disease progression. Defining the regulatory mechanism and diversity of CAF subtypes could identify potential therapeutic strategies to harness the tumor-suppressive activities of CAFs. To address this, we utilized single-cell RNA sequencing to profile fibroblast activation protein-α (FAP)–expressing mesenchymal cells in human PDAC. The mesenchymal subpopulations in PDAC reflected mesenchymal cell heterogeneity found in the normal developing pancreas. In addition to characterizing inflammatory CAF and myofibroblastic CAF subpopulations in detail, the analysis uncovered a previously undescribed interferon-response CAF (ifCAF) subtype. Tumor-derived signals induced specific CAF subtypes from pancreatic stellate cells in an organoid-based coculture model, and time-course experiments revealed regulatory mechanisms that govern subtype formation. STING agonists promoted an ifCAF phenotype in vivo and in vitro. Importantly, induction of an ifCAF phenotype suppressed tumor cell invasiveness and induced an antitumor phenotype in tumor-associated neutrophils. Together, this study resolves FAP<sup>+</sup> stromal cell heterogeneity in PDAC and identifies an ifCAF subtype that can be induced to suppress protumorigenic features of PDAC. Significance: Characterization of FAP<sup>+</sup> mesenchymal cell heterogeneity in pancreatic cancer identifies a tumor-suppressive interferon-response cancer-associated fibroblast subtype that can be induced by stimulating type I interferon signaling using STING agonists.</p>}},
  author       = {{Cumming, Joshua and Maneshi, Parniyan and Dongre, Mitesh and Alsaed, Tala and Dehghan-Nayeri, Mohammad Javad and Ling, Agnes and Pietras, Kristian and Patthey, Cedric and Öhlund, Daniel}},
  issn         = {{0008-5472}},
  language     = {{eng}},
  month        = {{07}},
  number       = {{13}},
  pages        = {{2388--2411}},
  publisher    = {{American Association for Cancer Research Inc.}},
  series       = {{Cancer Research}},
  title        = {{Dissecting FAP<sup>+</sup> Cell Diversity in Pancreatic Cancer Uncovers an Interferon-Response Subtype of Cancer-Associated Fibroblasts with Tumor-Restraining Properties}},
  url          = {{http://dx.doi.org/10.1158/0008-5472.CAN-23-3252}},
  doi          = {{10.1158/0008-5472.CAN-23-3252}},
  volume       = {{85}},
  year         = {{2025}},
}